Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. The Companyâ€™s clinical pipeline includes cirmtuzumab, TK216, ROR1 CAR-T. Cirmtuzumab is a monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). TK216 is a small molecule inhibiting the biological activity of E26 transformation-specific (ETS)-family transcription factor oncoproteins. The Company is also developing a ROR1-targeted CAR-T cell therapy candidate utilizing the binding domain of cirmtuzumab as a single-chain variable region fragment (scFv) for the treatment of patients with aggressive hematological malignancies or solid tumors.
Number of employees : 14 people.
|Novel Oncology Therapies||2.43||100%||3.38||100%|| +39.18%|
|USD in Million
|United States||2.43||100%||3.38||100%|| +39.18%|
|USD in Million
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Shanghai Pharmaceuticals Holding Co., Ltd ||3,544,431||
|The Vanguard Group, Inc. ||2,074,536||
|Armistice Capital LLC ||1,316,163||
|BlackRock Fund Advisors ||1,231,428||
|Nantahala Capital Management LLC ||1,200,747||
|Joseph R. Hyde ||1,176,871||
|SSgA Funds Management, Inc. ||807,637||
|Geode Capital Management LLC ||762,449||
|683 Capital Management LLC ||728,890||
|Hale BioPharma Ventures LLC ||713,152||
|Company contact information|
Oncternal Therapeutics, Inc.
12230 El Camino Real
San Diego, CA 92130
Phone : +1.858.434.1113
Fax : +858.408.3010
Web : http://www.oncternal.com
Sector Other Biotechnology & Medical Research
Connections : Oncternal Therapeutics, Inc.